Get the Stockscreener App
1.39
0.00%
0.00
After Hours:
1.38
-0.01
-0.72%
Pacific Biosciences Of California Inc stock is traded at $1.39, with a volume of 2.91M.
It is up +0.00% in the last 24 hours and down -14.72% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.39
Open:
$1.41
24h Volume:
2.91M
Relative Volume:
0.42
Market Cap:
$419.78M
Revenue:
$160.01M
Net Income/Loss:
$-546.38M
P/E Ratio:
-0.7575
EPS:
-1.835
Net Cash Flow:
$-118.92M
1W Performance:
+4.51%
1M Performance:
-14.72%
6M Performance:
+13.93%
1Y Performance:
+6.11%
1-Day Range:
$1.365
$1.45
1-Week Range:
$1.28
$1.45
52-Week Range:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.39 | 419.78M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California grants early SPRQ-Nx beta access to scientists for HiFi sequencing - Traders Union
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Analysis Recap: Can Pacific Biosciences of California Inc reach all time highs this yearTrade Volume Report & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Options Flow: Should I invest in Pacific Biosciences of California Inc before earningsMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Pacific Biosciences of California (PACB) Falls Further Than the Overall Market: Key Information to Note - Bitget
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Pacific Biosciences of California expands cancer research with new epigenetics lesson in sequencing series - Traders Union
DNA Sequencing Market size to hit $108.95 Billion by 2035 | Top - openPR.com
Canaccord reiterates Pacific Biosciences stock rating on new chemistry By Investing.com - Investing.com Canada
Canaccord reiterates Pacific Biosciences stock rating on new chemistry - Investing.com
PacBio (PACB) Collaborates on Groundbreaking Trillion Gene Atlas Project - GuruFocus
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative - marketscreener.com
Inside the trillion-gene atlas training AI to design new medicines - Stock Titan
Pacific Biosciences of California unveils DNA sequencing method boosting accuracy to 99.9 percent - Traders Union
Volume Summary: Does Pacific Biosciences of California Inc have a sustainable dividend2026 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
Pacific Biosciences of California urges last call for webinar on HiFi sequencing advances in cancer research - Traders Union
PacBio and DNAstack collaborate on global HiFi genome network hub - MSN
Pacific Biosciences of California introduces HiFi sequencing for comprehensive cancer analysis - Traders Union
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio - geneonline.com
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Pacific Biosciences of California technology maps cancer structural variants in single platform advance - Traders Union
PACB,TAL Options - Finviz
PACB,TAL Volatility & Greeks - Finviz
Chart Watch: Will Pacific Biosciences of California Inc outperform during market ralliesWeekly Earnings Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks - Yahoo Finance
HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts - Traders Union
Pacific Biosciences of California reports prelim Q4, FY revenue above estimate - MSN
Pacific Biosciences Secures Key Patent License, Ends Litigation - TipRanks
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
Patent deal locks in protections for Pacific Biosciences (NASDAQ: PACB) with PGI - Stock Titan
Pacific Biosciences of California, Inc. Announces Chief Accounting Officer Changes, Effective March 21, 2026 - marketscreener.com
PACB - Finviz
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News - GuruFocus
Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays - MarketBeat
Barclays downgrades Pacific Biosciences stock rating on catalysts By Investing.com - Investing.com Canada
Barclays downgrades Pacific Biosciences stock rating on catalysts - Investing.com UK
PacBio Announces the Appointment of Chris Gibson to the Board of Directors - Sahm
PacBio Adds AI-Driven Drug Discovery Leader to Board - The Globe and Mail
Pacific Biosciences of California unveils HiFi sequencing for comprehensive multiomic analysis - Traders Union
PacbBio Announces Appointment of Christopher Gibson to Board of Directors and Member of the Science and Technology Committee, Effective March 3, 2026 - marketscreener.com
Pacbio announces the appointment of Chris Gibson to the board of directors - marketscreener.com
PacBio Appoints New Board Member - Intellectia AI
AI biotech leader Chris Gibson joins PacBio (PACB) board of directors - Stock Titan
AI drug discovery founder from Recursion joins PacBio board - Stock Titan
Pacific Biosciences of California, Inc. $PACB Shares Sold by ARK Investment Management LLC - MarketBeat
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 By Investing.com - Investing.com Canada
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 - Investing.com
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 12,497 Shares - MarketBeat
PRISM 2026 set to shape genomics future, Pacific Biosciences of California asserts - Traders Union
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):